Ocular Therapeutix, Inc. (OCUL) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
OCUL EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
OCUL Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 87.3% | -521.0% | -513.2% |
| 2024 | 91.2% | -269.6% | -303.7% |
| 2023 | 91.0% | -141.0% | -138.1% |
| 2022 | 91.2% | -152.7% | -138.0% |
| 2021 | 89.9% | -179.3% | -15.1% |
Download Data
Export OCUL earnings history in CSV or JSON format
Free sign-in required to download data
Ocular Therapeutix, Inc. (OCUL) Earnings Overview
As of May 8, 2026, Ocular Therapeutix, Inc. (OCUL) reported trailing twelve-month net income of -$290M, reflecting -16.4% year-over-year growth. The company earned $-1.30 per diluted share over the past four quarters, with a net profit margin of -513.2%.
Looking at the long-term picture, OCUL's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2021.
Ocular Therapeutix, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCKT (-$223M net income), KALA (-$36M net income), ALDX (-$43M net income), OCUL has comparable earnings metrics. Compare OCUL vs RCKT →
OCUL Earnings vs Peers
Earnings metrics vs comparable public companies
OCUL Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$266M | -37.4% | -$270M | $-1.42 | -513.2% | -521.0% |
| 2024 | -$194M | -139.7% | -$172M | $-1.22 | -303.7% | -269.6% |
| 2023 | -$81M | -13.7% | -$82M | $-1.02 | -138.1% | -141.0% |
| 2022 | -$71M | -984.1% | -$79M | $-0.97 | -138.0% | -152.7% |
| 2021 | -$7M | +95.8% | -$78M | $-0.98 | -15.1% | -179.3% |
| 2020 | -$156M | -80.2% | -$63M | $-2.56 | -894.3% | -361.1% |
| 2019 | -$86M | -49.7% | -$86M | $-1.91 | -2043.3% | -2029.9% |
| 2018 | -$58M | +9.0% | -$59M | $-1.57 | -2899.1% | -2970.8% |
| 2017 | -$63M | -41.8% | -$62M | $-2.20 | -3296.2% | -3220.1% |
| 2016 | -$45M | -12.5% | -$43M | $-1.80 | -2369.0% | -2296.0% |
See OCUL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OCUL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OCUL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonOCUL — Frequently Asked Questions
Quick answers to the most common questions about buying OCUL stock.
Is OCUL growing earnings?
OCUL EPS fell to $-1.30, with earnings declining -16.4%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-290M.
What are OCUL's profit margins?
Ocular Therapeutix, Inc. net margin is -513.2%, with operating margin at -521.0%. Below-average margins reflect competitive or cost pressures.
How consistent are OCUL's earnings?
OCUL earnings data spans 2012-2025. The declining earnings trend is -16.4% YoY. Historical data enables comparison across business cycles.